Results 141 to 150 of about 131,629 (255)

Leveraging social media data to study disease and treatment characteristics of Hodgkin's lymphoma Using Natural Language Processing methods. [PDF]

PLOS Digit Health
Siddiqui ZA, Pathan M, Nduaguba S, LeMasters T, Scott VG, Sambamoorthi U, Patel JS.   +6 more
europepmc   +1 more source

Combination of fixed low‐dose nivolumab and bendamustine in children with high‐risk relapsed/refractory classical Hodgkin lymphoma

British Journal of Haematology, EarlyView.
A retrospective study of 18 pediatric patients with high‐risk relapsed/refractory classical Hodgkin lymphoma demonstrated that a fixed low‐dose combination of nivolumab and bendamustine achieved an 88% complete response rate, with 1‐year progression‐free survival (PFS) of 88.2% and overall survival (OS) of 94.4%.
Shyam Srinivasan, Aditya Narayan, Chetan Dhamne, Akanksha Chichra, Poonam Khemani, Nidhi Dhariwal, Raghwesh Ranjan, Sneha Shah, Tanuja Shet, Venkata Rama Mohan Gollamudi, Nirmalya Roy Moulik, Shripad D. Banavali, Gaurav Narula   +12 more
wiley   +1 more source

Coexistence of Tuberculous Lymphadenitis and Hodgkin Lymphoma: A Diagnostic Challenge. [PDF]

Cureus
Chandra M, Parmar M, Khilnani AK.
europepmc   +1 more source

Anaplastic large cell lymphoma in children and adolescents

British Journal of Haematology, EarlyView.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study. [PDF]

Cancer Immunol Immunother
Wu M, Sun P, Zhao B, Yang H, Xia Y, Nie M, Cai Q, Huang H, Huang H, Xia Z, Wang Y, Li Z, Liu P.   +12 more
europepmc   +1 more source

Hodgkin's disease. I. [PDF]

BMJ, 1967
openaire   +6 more sources

Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report [PDF]

, 2018
Bolwell, Brian, Cheverton, Peter D, DiPersio, John F, Horwitz, Mitchell E, Kaufman, Jonathan L, Maziarz, Richard T, McCarty, John M, Micallef, Ivana N, Nademanee, Auayporn P, Stadtmauer, Edward A, Stiff, Patrick J, Struijs, Martin, Vargo, Rita   +12 more
core   +2 more sources

Robust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion

British Journal of Haematology, EarlyView.
In this study, CAR T‐cell expansion and persistence were found to be comparable between CR and non‐CR groups, regardless of the co‐stimulatory domain (CD28 or 4‐1BB) or product used. Furthermore, peripheral blood kinetics—including absolute counts and proportions of total, CD4+ and CD8+ CAR T cells—showed no significant differences between the two ...
Ryo Hanajiri, Hiroya Wakabayashi, Kohei Ishigiwa, Fumiya Ohara, Shiho Hirano, Hirofumi Yokota, Shihomi Kuwano, Katsuya Furukawa, Kazuyuki Shimada, Takahiko Sato, Seitaro Terakura, Hitoshi Kiyoi   +11 more
wiley   +1 more source

Revealing Putative Causal Genes by Establishing the Causality Between Different Lymphomas and Immune Cells. [PDF]

J Cell Mol Med
Lian J, Zhang X, Chen W, Lin Z, Lu M, Liang R.   +5 more
europepmc   +1 more source

Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders [PDF]

, 2019
Chen, Chun-Cheng, Dharnidharka, Vikas R, Goss, Charles W, Gu, Hongjie, O\u27Gorman, Harry, Parameswaran, Priyanka, Ruzinova, Marianna B, Storch, Gregory A, Wylie, Kristine   +8 more
core   +2 more sources